BACKGROUND
A comprehensive understanding of the complexity and heterogeneity of the tumor microenvironment (TME) is critical for advancing cancer treatment. Recent advances in spatial omics technologies have opened new avenues for an in-depth exploration of the TME. By integrating high-resolution spatial information from omics, spatial omics enables the systematic characterization of the spatial distribution of various cell types within tissues and their interaction networks, providing a panoramic view of the TME. Emerging studies have highlighted that specific spatial structures within the TME are strongly associated with cancer prognosis and treatment responses.
AIM OF REVIEW
This review focuses on the patterns of spatial cell distributions or characteristic cell structures and their relationship with cancer prognosis, underscoring the pivotal role of spatial heterogeneity in tumors. It aims to provide theoretical foundations for precise medicine approaches in prognostic evaluation and therapy design.
KEY SCIENTIFIC CONCEPTS OF REVIEW
This review discusses how spatial transcriptomics and proteomics enable extraction of spatial metrics including cell density, proximity, and community-level organization. We further summarize the spatial distribution patterns of cells and key cell community structures, emphasizing the pivotal role of spatial heterogeneity in tumors. Furthermore, it highlights critical spatial features, including immune cell infiltration patterns and vascular niches, that are strongly linked to patient outcomes. Additionally, the review discusses the challenges and future prospects of applying spatial omics in clinical applications. As the field evolves, spatial omics holds transformative potential to revolutionize oncology research, enabling novel approaches for risk stratification and improving patient outcomes.
Xia Lei, Xuan Cui, Y. Ni et al.· Journal of Advanced Research· 0 citations
Mesenchymal stem cells (MSCs) have attracted considerable attention for clinical translation in regenerative medicine, primarily due to their validated paracrine effects, prominent immunomodulatory properties, and superior multipotent differentiation capabilities. However, the limited homing efficiency and poor post-transplant survival of MSCs severely compromise therapeutic efficacy, thereby giving rise to suboptimal and inconsistent treatment outcomes. To circumvent these critical drawbacks and fully harness the therapeutic potential of MSCs, researchers have incorporated a diverse array of effective strategies, including genetic engineering, preconditioning with cytokines, small molecular compounds or hypoxic stimuli, and scaffold-based culture systems. Given these promising research advances, this review systematically summarizes recent advances in MSC-enhanced therapeutic strategies, and elaborates on their core molecular mechanisms as well as how these mechanisms modulate MSC survival, homing capacity and immunomodulatory efficacy. On this basis, we further analyze the practical applicability of these enhanced MSCs in clinical trials and seek to provide critical insights for the clinical selection of MSC-based enhanced therapies.
Shanshan Zheng, Yukang Huang, Xianli Yang et al.· Frontiers in Cell and Develo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.